Regarding futibatinib, this agent has been tested in the single-arm, multicenter, phase II FOENIX-CCA2 trial that included previously treated CCA patients with FGFR2 gene fusions or other rearrangements. Here, FGFR2 is linked to cholangiocarcinoma.